OpGen Appoints R. Don Elsey to Board of Directors
26 February 2019 - 12:30AM
OpGen, Inc. (NASDAQ: OPGN) announces the
appointment R. Don Elsey to the company’s board of directors and
audit committee, effective February 21, 2019. He will serve
as chairman of the board’s audit committee and will stand for
reelection for a one-year term at the company’s next annual meeting
of stockholders, to be held in June 2019.
Mr. Elsey is a biotechnology, life sciences and
high technology industries veteran with more than three decades of
experience in international financial management and operations
with both large and small companies. Most recently he served as
chief financial officer of Senseonics, Inc., a position he held
from February 2015 to January 2019. Prior to Senseonics, he
was chief financial officer of Regado Biosciences Corporation. He
has also served as chief financial officer of LifeCell Corporation,
a privately held regenerative medicine company, and as chief
financial officer of Emergent Biosolutions, a biodefense company.
He also has held senior financial positions at BioVeris
Corporation, Igen, Inc. and PE Corporation (Applera).
“We are fortunate to welcome Don Elsey to the
OpGen board of directors,” said Evan Jones, the company’s chairman
and chief executive officer. “His deep and extensive financial and
public company experience will be invaluable to OpGen as we grow
into a leader in addressing the significant and increasingly dire
global health challenge of multidrug-resistant organisms.”
Mr. Elsey currently serves on the board of
directors and audit committee for RegeneRx Biopharmaceuticals, Inc.
and on the board of directors and treasurer for Cancer Support
Community. He holds a BA in economics and an MBA in finance from
Michigan State University, and is a certified management
accountant.
About OpGen
OpGen, Inc. is a precision medicine company
harnessing the power of molecular diagnostics and informatics to
help combat infectious disease. We are developing molecular
information products and services for global healthcare settings,
helping to guide clinicians with more rapid and actionable
information about life threatening infections, improve patient
outcomes, and decrease the spread of infections caused by
multidrug-resistant microorganisms, or MDROs. Our proprietary DNA
tests and informatics address the rising threat of antibiotic
resistance by helping physicians and other healthcare providers
optimize care decisions for patients with acute
infections.
Our molecular diagnostics and informatics
products, product candidates and services combine our Acuitas®
molecular diagnostics and Acuitas Lighthouse® informatics platform
for use with our proprietary, curated MDRO knowledgebase. We are
working to deliver our products and services, some in development,
to a global network of customers and partners. Currently we offer
our Acuitas AMR Gene Panel tests for research use only. For more
information, please visit www.opgen.com.
OpGen, Acuitas, and Acuitas Lighthouse are
registered trademarks of OpGen, Inc.
OpGen Contact: Michael Farmer Vice President,
Marketing (240)
813-1284mfarmer@opgen.comInvestorRelations@opgen.com
Investor Contacts: LHA Investor Relations Kim
Sutton Golodetz (212) 838-3777kgolodetz@lhai.com or Bruce Voss
(310) 691-7100 bvoss@lhai.com
Media ContactMatt BretziusFischTank Marketing
and PRmatt@fischtankpr.com
OpGen (NASDAQ:OPGN)
Historical Stock Chart
From Aug 2024 to Sep 2024
OpGen (NASDAQ:OPGN)
Historical Stock Chart
From Sep 2023 to Sep 2024